Literature DB >> 15358166

Involvement of p38 signaling pathway in interferon-alpha-mediated antiviral activity toward hepatitis C virus.

Hisashi Ishida1, Kazuyoshi Ohkawa, Atsushi Hosui, Naoki Hiramatsu, Tatsuya Kanto, Keiji Ueda, Tetsuo Takehara, Norio Hayashi.   

Abstract

We studied the involvement of the p38 signaling pathway in the interferon (IFN)-alpha-mediated antiviral activity toward hepatitis C virus (HCV) using HCV subgenomic replicon cells. When the cells were treated with IFN-alpha in the presence of p38 inhibitor, the suppressive effect of IFN-alpha on replicon RNA was reduced. Inhibition of p38 had almost no influence on phosphorylation of signal transducer and activator transcription factor 1 (STAT1) and interferon stimulatory response element-dependent gene expression after IFN-alpha treatment. This indicates that the anti-HCV activity through p38 may be independent of the Janus kinase-STAT pathway. Treatment with the inhibitor of the mitogen-activated protein kinase-activated protein kinase 2 (MK2) showed the same level of reduction in the IFN-alpha-mediated anti-HCV activity as that with the p38 inhibitor. Thus, MK2 may also be responsible for the anti-HCV activity through p38. In conclusion, the p38-MK2 signaling pathway may be substantially involved in the IFN-alpha-mediated anti-HCV activity.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15358166     DOI: 10.1016/j.bbrc.2004.07.015

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  13 in total

1.  Expression patterns and action analysis of genes associated with hepatitis virus infection during rat liver regeneration.

Authors:  Li-Juan Su; Guang-Wei Ding; Zhi-Li Yang; Shou-Bing Zhang; Yu-Xiu Yang; Cun-Shuan Xu
Journal:  World J Gastroenterol       Date:  2006-12-21       Impact factor: 5.742

2.  The Ebolavirus VP24 protein blocks phosphorylation of p38 mitogen-activated protein kinase.

Authors:  Peter Halfmann; Gabriele Neumann; Yoshihiro Kawaoka
Journal:  J Infect Dis       Date:  2011-11       Impact factor: 5.226

3.  Identification of Piperazinylbenzenesulfonamides as New Inhibitors of Claudin-1 Trafficking and Hepatitis C Virus Entry.

Authors:  Laura Riva; Ok-Ryul Song; Jannick Prentoe; François Helle; Laurent L'homme; Charles-Henry Gattolliat; Alexandre Vandeputte; Lucie Fénéant; Sandrine Belouzard; Thomas F Baumert; Tarik Asselah; Jens Bukh; Priscille Brodin; Laurence Cocquerel; Yves Rouillé; Jean Dubuisson
Journal:  J Virol       Date:  2018-04-27       Impact factor: 5.103

4.  Novel alpha interferon (IFN-alpha) variant with improved inhibitory activity against hepatitis C virus genotype 1 replication compared to IFN-alpha2b therapy in a subgenomic replicon system.

Authors:  Vanessa Escuret; Amaury Martin; David Durantel; Romain Parent; Olivier Hantz; Christian Trépo; Thierry Menguy; Emmanuel Bottius; Jerome Dardy; Jean Maral; Jean Louis Escary; Fabien Zoulim
Journal:  Antimicrob Agents Chemother       Date:  2006-10-09       Impact factor: 5.191

Review 5.  Tumor viruses and cancer biology: Modulating signaling pathways for therapeutic intervention.

Authors:  Abhik Saha; Rajeev Kaul; Masanao Murakami; Erle S Robertson
Journal:  Cancer Biol Ther       Date:  2010-11-15       Impact factor: 4.742

Review 6.  Immunomodulatory functions of type I interferons.

Authors:  José M González-Navajas; Jongdae Lee; Michael David; Eyal Raz
Journal:  Nat Rev Immunol       Date:  2012-01-06       Impact factor: 53.106

7.  Mnk Kinases in Cytokine Signaling and Regulation of Cytokine Responses.

Authors:  Sonali Joshi; Leonidas C Platanias
Journal:  Biomol Concepts       Date:  2012-04

8.  Contrasting roles of mitogen-activated protein kinases in cellular entry and replication of hepatitis C virus: MKNK1 facilitates cell entry.

Authors:  Seungtaek Kim; Hisashi Ishida; Daisuke Yamane; MinKyung Yi; David C Swinney; Steven Foung; Stanley M Lemon
Journal:  J Virol       Date:  2013-01-30       Impact factor: 5.103

9.  Interferon alpha regulates MAPK and STAT1 pathways in human hepatoma cells.

Authors:  Lan-Juan Zhao; Xian Hua; Sheng-Fei He; Hao Ren; Zhong-Tian Qi
Journal:  Virol J       Date:  2011-04-06       Impact factor: 4.099

10.  Rosiglitazone, an Agonist of PPARgamma, Inhibits Non-Small Cell Carcinoma Cell Proliferation In Part through Activation of Tumor Sclerosis Complex-2.

Authors:  Shouwei Han; Ying Zheng; Jesse Roman
Journal:  PPAR Res       Date:  2007       Impact factor: 4.964

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.